表 2. Complications for intravesical therapy.
膀胱灌注治疗相关并发症
| Complication | BCG group/case (%) | EPI group/case (%), n=21 | P1 | P2 | ||
| Total (n=72) | 19 times group (n=35) | 15 times group (n=37) | ||||
| BCG: Bacillus Calmette–Guérin; EPI: Epirubicin; CTCAE: Common Terminology Criteria for Adverse Events; Others: Rare complications including respiratory infection, hypertension and hyperglycemia. P1: BCG 19 times group vs. BCG 15 times group; P2: BCG group vs. EPI group. | ||||||
| Urocystitis | 54 (75.0) | 27 (77.1) | 27 (73.0) | 11 (52.4) | 0.683 | 0.047 |
| Hematuresis | 31 (43.1) | 17 (48.6) | 14 (37.8) | 9 (42.9) | 0.358 | 0.987 |
| Fever | 12 (16.7) | 5 (14.3) | 7 (18.9) | 0 (0.0) | 0.598 | 0.062 |
| Others | 21 (29.2) | 9 (25.7) | 12 (32.4) | 2 (9.5) | 0.353 | 0.122 |
| CTCAE grade | ||||||
| 1 | 53 (73.6) | 29 (82.9) | 24 (64.9) | 13 (61.9) | − | − |
| 2 | 8 (11.1) | 2 (5.7) | 6 (16.2) | 0 (0.0) | − | − |
| 3−5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | − | − |
| Total adverse events | 61 (84.7) | 31 (88.6) | 30 (81.1) | 13 (61.9) | 0.226 | 0.022 |